<p>Avitas Wealth Management LLC 在第二季度增持了阿斯利康（AstraZeneca PLC）的股份，根据最近向美国证券交易委员会（SEC）披露的信息，持股比例增加了 23.0%。该公司在此期间购入了 8,947 股，持有该公司股票 47,803 股。Avitas Wealth Management LLC 在最新一次向 SEC 提交的文件中，持有的阿斯利康股份价值 3,728,000 美元。</p>
<ul>
<li>逆市表现：3 家市值巨大的公司股价飙升至新高</li>
</ul>
<p>其他机构投资者最近也买入和卖出了该公司的股票。Assetmark Inc.在第四季度增加了对阿斯利康股份的持股比例 11.2%。Assetmark Inc.现在拥有 154,906 股该公司股票，价值 10,433,000 美元，较之前增加了 15,642 股。Cox Capital Mgt LLC 在第一季度以 2,683,000 美元的价值新建了阿斯利康的头寸。TD Asset Management Inc 在第一季度将其对阿斯利康股份的持股比例提高了 8.6%。TD Asset Management Inc 现在拥有 1,537,410 股该公司股票，价值 104,160,000 美元，较之前增加了 121,876 股。Wealthcare Advisory Partners LLC 在第一季度将其对阿斯利康股份的持股比例提高了 9.7%。Wealthcare Advisory Partners LLC 现在拥有 6,136 股该公司股票，价值 416,000 美元，较上一季度增加了 543 股。最后，Cetera Advisors LLC 在第一季度将其对阿斯利康股份的持股比例提高了 124.5%。Cetera Advisors LLC 现在拥有 98,262 股该公司股票，价值 6,657,000 美元，较之前增加了 54,488 股。机构投资者和对冲基金拥有该公司股份的 20.35%。</p>
<h2>阿斯利康股价表现</h2>
<p>周五，AZN 股价上涨 0.77 美元，达到 86.66 美元。该股交易量为 3,336,004 股，相比平均交易量 5,313,068 股有所下降。该公司的市值为 268.69 亿美元，市盈率为 42.48，PEG 比率为 1.36，贝塔系数为 0.45。公司的资产负债比为 0.69，流动比率为 0.89，速动比率为 0.69。阿斯利康 PLC 的 12 个月最低价为 60.47 美元，最高价为 86.88 美元。该公司的 50 日移动平均股价为 79.96 美元，200 日移动平均股价为 74.01 美元。</p>
<ul>
<li>尽管超出盈利预期并提高了业绩指引，阿斯利康股价下跌</li>
</ul>
<p>阿斯利康（NASDAQ:AZN）上次发布季度盈利报告是在 7 月 25 日星期四。该公司报告本季度每股盈利为 0.99 美元，超过分析师预期的 0.98 美元。本季度公司营收为 124.5 亿美元，略低于市场预期的 126.2 亿美元。阿斯利康的净利润率为 13.11%，净资产回报率为 29.34%。公司本季度营收同比增长了 9.1%。在去年同期，公司每股盈利为 1.08 美元。卖方分析师预测，阿斯利康 PLC 本财年每股盈利将达到 4.74 美元。</p>
<h2>阿斯利康削减股息</h2>
<p>该公司最近宣布将支付半年度股息，股息将于 9 月 9 日星期一支付。股权登记日为 8 月 9 日星期五，将支付 0.49 美元的股息。该股息的除息日为 8 月 9 日星期五。这代表股息率为 1.8%。阿斯利康的派息比率为 48.04%。</p>
<h2>分析师设定新的股价目标</h2>
<ul>
<li>以 GLP-1 需求推动的 Eli Lilly 股价飙升</li>
</ul>
<p>一些股票研究分析师已经发布了关于该股的报告。BMO Capital Markets 将阿斯利康股价目标从 80.00 美元上调至 82.00 美元，并在 4 月 26 日的研究报告中给予该股 “表现优异” 评级。巴克莱将阿斯利康评级提升至 “强热门” 评级，并在 6 月 24 日的报告中提及。花旗集团在 6 月 24 日的报告中将阿斯利康评级提升至 “强热门” 评级。高盛集团在 5 月 30 日的研究报告中开始对阿斯利康股票进行覆盖。他们给出了 “买入” 评级，并设定了 97.00 美元的股价目标。最后，阿格斯在 5 月 30 日的研究报告中将阿斯利康股价目标从 80.00 美元上调至 85.00 美元，并给予该股 “买入” 评级。三位投资分析师对该股的评级为持有，六位给出买入评级，三位给出强热门评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “买入”，平均目标股价为 89.75 美元。</p>
<p><strong>查看我们关于阿斯利康的最新报告</strong></p>
<h2>阿斯利康简介（免费报告）</h2>
<p>阿斯利康 PLC 是一家生物制药公司，专注于处方药物的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，用于心血管、肾脏、代谢和肿瘤领域。</p>
<h2>另请参阅</h2>
<ul>
<li>我们喜欢的五支股票胜过阿斯利康</li>
<li>3 家 2021 年前景良好的金融科技股</li>
<li>Lumen：上个月表现最佳的公司之一，仍有警示信号</li>
<li>即将上市的股票解禁期，解释</li>
<li>百度强劲季度证明迈克尔·伯里的明智选择</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>Intuit 击败第四季度盈利：人工智能、股息和增长策略</li>
</ul>
<p><strong>想看看其他对阿斯利康持有 AZN 的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取最新的 13F 申报和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 5 支股票可能在一周内翻三倍（来自交易机构）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjMz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjMz"/></p>
<h2>现在是否值得投资 1000 美元购买阿斯利康？</h2>
<p>在考虑是否购买阿斯利康之前，您可能希望听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉他们的客户现在购买的股票，希望在更广泛市场关注之前买入...而阿斯利康并不在名单上。</p>
<p>尽管阿斯利康目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

阿斯利康

<p>Avitas Wealth Management LLC 在第二季度增持了阿斯利康（AstraZeneca PLC，NASDAQ:AZN）的持股，增幅为 23.0%，增持了 8,947 股。该公司目前持有总值$2,728,000 的 47,803 股。其他机构投资者也增加了对阿斯利康的持股。该公司最近公布的季度收入超出预期，同比增长了 9.1%。此外，公司宣布了半年度股息，股息率为 1.8%。分析师们对阿斯利康股票保持 “买入” 共识，并给出了一个有利的平均目标价</p>

<p>Avitas Wealth Management LLC increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 23.0% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 47,803 shares of the company's stock after purchasing an additional 8,947 shares during the period. Avitas Wealth Management LLC's holdings in AstraZeneca were worth $3,728,000 as of its most recent filing with the SEC.</p>
<ul>
<li>Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs</li>
</ul>
<div class="lb-trans"><p>Avitas Wealth Management LLC 在第二季度增持了阿斯利康（AstraZeneca PLC）的股份，根据最近向美国证券交易委员会（SEC）披露的信息，持股比例增加了 23.0%。该公司在此期间购入了 8,947 股，持有该公司股票 47,803 股。Avitas Wealth Management LLC 在最新一次向 SEC 提交的文件中，持有的阿斯利康股份价值 3,728,000 美元。</p>
<ul>
<li>逆市表现：3 家市值巨大的公司股价飙升至新高</li>
</ul>
</div><p>Other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. boosted its stake in shares of AstraZeneca by 11.2% during the 4th quarter. Assetmark Inc. now owns 154,906 shares of the company's stock worth $10,433,000 after acquiring an additional 15,642 shares during the period. Cox Capital Mgt LLC acquired a new position in shares of AstraZeneca in the first quarter valued at $2,683,000. TD Asset Management Inc raised its position in shares of AstraZeneca by 8.6% in the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company's stock valued at $104,160,000 after purchasing an additional 121,876 shares during the period. Wealthcare Advisory Partners LLC lifted its stake in shares of AstraZeneca by 9.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company's stock worth $416,000 after buying an additional 543 shares during the last quarter. Finally, Cetera Advisors LLC boosted its holdings in shares of AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company's stock worth $6,657,000 after buying an additional 54,488 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也买入和卖出了该公司的股票。Assetmark Inc.在第四季度增加了对阿斯利康股份的持股比例 11.2%。Assetmark Inc.现在拥有 154,906 股该公司股票，价值 10,433,000 美元，较之前增加了 15,642 股。Cox Capital Mgt LLC 在第一季度以 2,683,000 美元的价值新建了阿斯利康的头寸。TD Asset Management Inc 在第一季度将其对阿斯利康股份的持股比例提高了 8.6%。TD Asset Management Inc 现在拥有 1,537,410 股该公司股票，价值 104,160,000 美元，较之前增加了 121,876 股。Wealthcare Advisory Partners LLC 在第一季度将其对阿斯利康股份的持股比例提高了 9.7%。Wealthcare Advisory Partners LLC 现在拥有 6,136 股该公司股票，价值 416,000 美元，较上一季度增加了 543 股。最后，Cetera Advisors LLC 在第一季度将其对阿斯利康股份的持股比例提高了 124.5%。Cetera Advisors LLC 现在拥有 98,262 股该公司股票，价值 6,657,000 美元，较之前增加了 54,488 股。机构投资者和对冲基金拥有该公司股份的 20.35%。</p>
</div><h2>AstraZeneca Price Performance</h2>
<div class="lb-trans"><h2>阿斯利康股价表现</h2>
</div><p>AZN traded up $0.77 on Friday, hitting $86.66. 3,336,004 shares of the stock were exchanged, compared to its average volume of 5,313,068. The firm has a market capitalization of $268.69 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 1.36 and a beta of 0.45. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $86.88. The business has a 50-day moving average of $79.96 and a two-hundred day moving average of $74.01.</p>
<ul>
<li>AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance</li>
</ul>
<div class="lb-trans"><p>周五，AZN 股价上涨 0.77 美元，达到 86.66 美元。该股交易量为 3,336,004 股，相比平均交易量 5,313,068 股有所下降。该公司的市值为 268.69 亿美元，市盈率为 42.48，PEG 比率为 1.36，贝塔系数为 0.45。公司的资产负债比为 0.69，流动比率为 0.89，速动比率为 0.69。阿斯利康 PLC 的 12 个月最低价为 60.47 美元，最高价为 86.88 美元。该公司的 50 日移动平均股价为 79.96 美元，200 日移动平均股价为 74.01 美元。</p>
<ul>
<li>尽管超出盈利预期并提高了业绩指引，阿斯利康股价下跌</li>
</ul>
</div><p>AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm's quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.08 EPS. Sell-side analysts forecast that AstraZeneca PLC will post 4.74 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿斯利康（NASDAQ:AZN）上次发布季度盈利报告是在 7 月 25 日星期四。该公司报告本季度每股盈利为 0.99 美元，超过分析师预期的 0.98 美元。本季度公司营收为 124.5 亿美元，略低于市场预期的 126.2 亿美元。阿斯利康的净利润率为 13.11%，净资产回报率为 29.34%。公司本季度营收同比增长了 9.1%。在去年同期，公司每股盈利为 1.08 美元。卖方分析师预测，阿斯利康 PLC 本财年每股盈利将达到 4.74 美元。</p>
</div><h2>AstraZeneca Cuts Dividend</h2>
<div class="lb-trans"><h2>阿斯利康削减股息</h2>
</div><p>The firm also recently declared a Semi-Annual dividend, which will be paid on Monday, September 9th. Stockholders of record on Friday, August 9th will be paid a $0.49 dividend. The ex-dividend date of this dividend is Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca's payout ratio is 48.04%.</p>
<div class="lb-trans"><p>该公司最近宣布将支付半年度股息，股息将于 9 月 9 日星期一支付。股权登记日为 8 月 9 日星期五，将支付 0.49 美元的股息。该股息的除息日为 8 月 9 日星期五。这代表股息率为 1.8%。阿斯利康的派息比率为 48.04%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<ul>
<li>Eli Lilly's Stock Surge Driven by GLP-1 Demand</li>
</ul>
<div class="lb-trans"><h2>分析师设定新的股价目标</h2>
<ul>
<li>以 GLP-1 需求推动的 Eli Lilly 股价飙升</li>
</ul>
</div><p>Several equities research analysts have issued reports on the stock. BMO Capital Markets raised their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, April 26th. Barclays raised AstraZeneca to a &#34;strong-buy&#34; rating in a report on Monday, June 24th. Citigroup raised AstraZeneca to a &#34;strong-buy&#34; rating in a report on Monday, June 24th. The Goldman Sachs Group started coverage on shares of AstraZeneca in a research note on Thursday, May 30th. They issued a &#34;buy&#34; rating and a $97.00 price target on the stock. Finally, Argus lifted their price objective on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, May 30th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Buy&#34; and an average target price of $89.75.</p>
<div class="lb-trans"><p>一些股票研究分析师已经发布了关于该股的报告。BMO Capital Markets 将阿斯利康股价目标从 80.00 美元上调至 82.00 美元，并在 4 月 26 日的研究报告中给予该股 “表现优异” 评级。巴克莱将阿斯利康评级提升至 “强热门” 评级，并在 6 月 24 日的报告中提及。花旗集团在 6 月 24 日的报告中将阿斯利康评级提升至 “强热门” 评级。高盛集团在 5 月 30 日的研究报告中开始对阿斯利康股票进行覆盖。他们给出了 “买入” 评级，并设定了 97.00 美元的股价目标。最后，阿格斯在 5 月 30 日的研究报告中将阿斯利康股价目标从 80.00 美元上调至 85.00 美元，并给予该股 “买入” 评级。三位投资分析师对该股的评级为持有，六位给出买入评级，三位给出强热门评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “买入”，平均目标股价为 89.75 美元。</p>
</div><p><strong>View Our Latest Report on AstraZeneca</strong></p>
<div class="lb-trans"><p><strong>查看我们关于阿斯利康的最新报告</strong></p>
</div><h2>AstraZeneca Profile (Free Report)</h2>
<div class="lb-trans"><h2>阿斯利康简介（免费报告）</h2>
</div><p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p>
<div class="lb-trans"><p>阿斯利康 PLC 是一家生物制药公司，专注于处方药物的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，用于心血管、肾脏、代谢和肿瘤领域。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than AstraZeneca</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Lumen: Among Top Performers Last Month, Still Has Warning Signs</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Baidu's Strong Quarter Proves a Smart Pick for Michael Burry</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy</li>
</ul>
<div class="lb-trans"><h2>另请参阅</h2>
<ul>
<li>我们喜欢的五支股票胜过阿斯利康</li>
<li>3 家 2021 年前景良好的金融科技股</li>
<li>Lumen：上个月表现最佳的公司之一，仍有警示信号</li>
<li>即将上市的股票解禁期，解释</li>
<li>百度强劲季度证明迈克尔·伯里的明智选择</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>Intuit 击败第四季度盈利：人工智能、股息和增长策略</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AZN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对阿斯利康持有 AZN 的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取最新的 13F 申报和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AZN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ 5 Stocks that could triple in a week (From Traders Agency)(Ad)</p>
<div class="lb-trans"><p>→ 5 支股票可能在一周内翻三倍（来自交易机构）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjMz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9233&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AstraZeneca right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买阿斯利康？</h2>
</div><p>Before you consider AstraZeneca, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑是否购买阿斯利康之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉他们的客户现在购买的股票，希望在更广泛市场关注之前买入...而阿斯利康并不在名单上。</p>
</div><p>While AstraZeneca currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管阿斯利康目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Avitas Wealth Management LLC 购买了 8,947 股阿斯利康公司（NASDAQ:AZN）的股票